KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biomarin Pharmaceutical (BMRN) Accumulated Depreciation & Amortization (2016 - 2025)

Biomarin Pharmaceutical's Accumulated Depreciation & Amortization history spans 16 years, with the latest figure at $79.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization fell 17.49% year-over-year to $79.6 million, compared with a TTM value of $79.6 million through Dec 2025, down 17.49%, and an annual FY2025 reading of $79.6 million, down 17.49% over the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $79.6 million at Biomarin Pharmaceutical, up from $59.1 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $108.0 million in Q4 2021, with the low at $22.1 million in Q1 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $62.2 million, with a median of $57.2 million recorded in 2021.
  • Year-over-year, Accumulated Depreciation & Amortization grew 7.88% in 2021 and then fell 24.49% in 2025.
  • Tracing BMRN's Accumulated Depreciation & Amortization over 5 years: stood at $108.0 million in 2021, then fell by 5.62% to $102.0 million in 2022, then increased by 2.37% to $104.4 million in 2023, then dropped by 7.63% to $96.4 million in 2024, then dropped by 17.49% to $79.6 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Accumulated Depreciation & Amortization are $79.6 million (Q4 2025), $59.1 million (Q3 2025), and $40.6 million (Q2 2025).